Jefferies Maintains Buy on Veradermics, Raises Price Target to $182

Veradermics, Incorporated

Veradermics, Incorporated

MANE

0.00

Jefferies analyst Roger Song maintains Veradermics (NYSE: MANE) with a Buy and raises the price target from $138 to $182.